title: [Positron emission tomography with 18-fluorine deoxyglucose in the diagnosis and assessment of prostate cancer].
abstract: Results of PET studies using 18-fluorine deoxyglucose (18-FDG) in patients with large-size masses (51) are discussed. Histologically-confirmed prostate cancer was diagnosed in 36 (70.5%), benign hyperplasia--12 (23.5%) and chronic prostatitis--3(6%). 18FDG PET was conducted as whole body irradiation. Our results established its high predictive significance in identifying the scope of tumor involvement. However, the latter's potential is limited in diagnosis of primary tumor node due to low rate of glycolysis in it.
authors.forename: D V
authors.initials: DV
authors.lastname: Ryzhkova
authors.forename: M I
authors.initials: MI
authors.lastname: Shkol'nik
authors.forename: M I
authors.initials: MI
authors.lastname: Karelin
authors.forename: A A
authors.initials: AA
authors.lastname: Arzumanov
authors.forename: A A
authors.initials: AA
authors.lastname: Stanzhevskiĭ
authors.forename: M S
authors.initials: MS
authors.lastname: Tlostanova
mesh_terms: D000368:Aged; D002908:Chronic Disease; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D011472:Prostatitis / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals; D014463:Ultrasonography; D014916:Whole-Body Irradiation
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18